WebApr 19, 2024 · Public. Description. Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted throughout the oncology community as the standard classification and severity grading scale for adverse events in cancer therapy clinical trials and other oncology settings. Version 5 was published by the NCI Cancer Therapy … WebApr 12, 2024 · A phase I/II open label, single-center study of the safety, tolerability, and efficacy of peri- and postoperative therapy with histamine dihydrochloride and low-dose …
Histamine Dihydrochloride and Interleukin-2 in Primary …
WebApr 5, 2024 · Listing a study does not mean it has been evaluated by the U.S. Federal Government. ... [NCI] Common Terminology Criteria for Adverse Events Version 5.0 [CTCAE 5.0]); Subjects with any severe and/or uncontrolled disease. ... Qi Zhou, Professor, Chongqing University Cancer Hospital: ClinicalTrials.gov Identifier: NCT05799469 Other … WebVersion of the Common Terminology Criteria for Adverse Events) in the management of children with cancer, in the clinical research setting especially in the context of new drug fly babies play
Patient-Reported Outcomes version of the Common Terminology …
WebJan 8, 2024 · Originally developed for oncology trials by the National Cancer Institute (NCI), the CTCAE is now used widely across all types of clinical trials, and as a result has become an essential tool for evaluating trial safety. The CTCAE provides a library of over 800 AEs with guidelines for grading event severity. WebThe toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A follow-up CT scan was obtained every 2 cycles of chemotherapy to evaluate the treatment effect unless abnormalities were found on the physical exam or in the laboratory data. WebAim: This study aims to compare acute toxicity of prostate cancer (PCa) stereotactic body radiotherapy (SBRT) delivered by MR-guided radiotherapy (MRgRT) with 1.5-T MR-linac or by volumetric modulated arc (VMAT) with conventional linac. Methods: Patients with low-to-favorable intermediate risk class PCa were treated with exclusive SBRT (35 Gy in five … greenhouse farming technology